APA

Gianolio D. A., Rouleau C., Bauta W. E., Lovett D., Cantrell W. R., Recio A., Wolstenholme-Hogg P., Busch M., Pan P., Stefano J. E., Kramer H. M., Goebel J., Krumbholz R. D., Roth S., Schmid S. M. & Teicher B. A. (20121105). Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. : Cancer chemotherapy and pharmacology.

Chicago

Gianolio Diego A, Rouleau Cecile, Bauta William E, Lovett Dennis, Cantrell William R, Recio Antonio, Wolstenholme-Hogg Paul, Busch Michelle, Pan Peng, Stefano James E, Kramer Hildegard M, Goebel James, Krumbholz Roy D, Roth Stephanie, Schmid Steven M and Teicher Beverly A. 20121105. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. : Cancer chemotherapy and pharmacology.

Harvard

Gianolio D. A., Rouleau C., Bauta W. E., Lovett D., Cantrell W. R., Recio A., Wolstenholme-Hogg P., Busch M., Pan P., Stefano J. E., Kramer H. M., Goebel J., Krumbholz R. D., Roth S., Schmid S. M. and Teicher B. A. (20121105). Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. : Cancer chemotherapy and pharmacology.

MLA

Gianolio Diego A, Rouleau Cecile, Bauta William E, Lovett Dennis, Cantrell William R, Recio Antonio, Wolstenholme-Hogg Paul, Busch Michelle, Pan Peng, Stefano James E, Kramer Hildegard M, Goebel James, Krumbholz Roy D, Roth Stephanie, Schmid Steven M and Teicher Beverly A. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates. : Cancer chemotherapy and pharmacology. 20121105.